Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

West China’s pharma manufacturing lagging behind other regions, observes GlobalData

Western China’s pharmaceutical production needs international and domestic investment, as there less number of facilities compared to other Chinese regions and few international pharma companies or CMOs in the region given its geographic size, says GlobalData, a leading data and analytics company Adam Bradbury, PharmSource Analyst at GlobalData, comments: “There may be limits on international […]
Read more

Several US states are easing COVID-19 restrictions too early, says GlobalData

Texas and several other states such as Mississippi, Louisiana, and Michigan rescinding previous executive orders that were intended to slow the spread of COVID-19 could cause an emergence of more transmissible variants, says GlobalData, a leading data and analytics company. Walter Gabriel, MPH, Epidemiologist at GlobalData, comments: “The decision to ease restrictions comes in the […]
Read more

Accelerated deal-making activity promises delivery of late-stage clinical candidates in head and neck cancer, says GlobalData

Rising strategic partnerships between global pharmaceutical companies to develop therapies in the head and neck cancer space can serve as opportunities for increased scientific development and business collaborations, says GlobalData, a leading data and analytics company. Aarohi Rede, BDS, MPH, Oncology Analyst at GlobalData, comments: “The past few years have seen several licensing deals globally […]
Read more

Cipla takes deal route with Alvotech to enter Australian autoimmune biosimilars market, says GlobalData

Australia continues to focus on reducing healthcare expenditure and encouraging the use of biosimilars over their reference product. Cipla adopted deals route to capitalize on the opportunities that exist within the Australian biosimilars space, says GlobalData, a leading data and analytics company. On 02 March 2021, Cipla Gulf and Alvotech expanded their partnership to market […]
Read more

Mylan’s merger with UpJohn as Viatris provides significant opportunity to focus on biosimilar launch and uptake

Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s Novolog/NovoRapid (insulin aspart); Samisha Khangaonkar, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “While Key Opinion Leaders (KOLs) interviewed by GlobalData are relatively brand agnostic when prescribing rapid-acting insulin analogs, there is a […]
Read more

Diagnosed prevalent cases of chronic kidney disease-anemia to reach 4.5 million by 2029 in the 8MM, says GlobalData

The diagnosed prevalent cases of chronic kidney disease-anemia (CKD-anemia) in the eight major markets (*8MM) are projected to increase from four million cases in 2019 to 4.5 million cases in 2029, equating to an annual growth rate (AGR) of 1.13%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Chronic Kidney Disease-Anemia – […]
Read more

Stellar progress has been made on vaccines at the one-year anniversary of COVID-19 in the US, says GlobalData

At the one-year anniversary of the World Health Organization’s official declaration of the COVID-19 pandemic, there has been record-breaking progress made towards developing a COVID-19 vaccine and vaccination in the US. However, the threat that variants could reduce vaccine effectiveness remains, though recent results indicate that vaccines could still have a 100% efficacy against severe […]
Read more

China continues to dominate high value oncology strategic deals in Asia-Pacific, reveals GlobalData

High value deals have dominated the Asia-Pacific (APAC) pharmaceutical strategic partnership landscape in 2020. Within the region, China is well ahead of other countries, particularly in the field of oncology, reveals GlobalData, a leading data and analytics company. Ms. Sasmitha Sahu, Pharma Analyst at GlobalData, comments: “China has tackled the COVID-19 pandemic effectively and restarted […]
Read more

CRISPR-based cancer therapies have potential to be a disruptive technology in healthcare, according to GlobalData

Clustered regularly interspaced short palindromic repeat (CRISPR) therapies are one of the most potentially powerful and transformative technologies in human history, according to GlobalData, a leading data and analytics company. Expected to be able to prolong the life of cancer patients by decades, compared to the current performance of blockbuster drugs that prolong life by […]
Read more
1 … 68 69 70 71 72 … 110